/ETBI

ETBI Stock - Eastgate Biotech Corp.

Q: What is the analyst price target for ETBI?

Analyst price target information is not currently available for ETBI.

Q: What is ETBI's market cap?

Market capitalization information is not currently available for ETBI.

Healthcare|Medical - Pharmaceuticals|OTC

$0.00+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for ETBI

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2015

FY2016

FY2017

FY2018

FY2019

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta3.42

52W High$0.00

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2019	FY2018	FY2017	FY2016	FY2015
Revenue	$99,735	$136,125	$157,379	N/A	$132,025
Gross Profit	$-110,079	$-68,881	$-3,036	N/A	$112,830
Gross Margin	-110.4%	-50.6%	-1.9%	N/A	85.5%
Operating Income	$-3,273,690	$-1,346,480	$-3,431,270	$-2,633,514	$-4,171,386
Net Income	$-3,544,249	$-1,497,815	$-3,719,462	$-2,977,471	$-4,281,310
Net Margin	-3553.7%	-1100.3%	-2363.4%	N/A	-3242.8%
EPS	$-0.00	$-0.00	$0.00	$-0.01	$-0.02

Company Overview

EastGate Biotech Corp. is a pharmaceutical company. The Company produces and distributes nutraceuticals that are based on natural therapies and absorbed naturally by the body. It utilizes state-of-the-art nanotechnologies to deliver healthy alternatives to conventional pharmaceuticals that all too often create dangerous side effects and unexpected consequences for those trying to attain and maintain healthy lives. The Company’s products include E-Drops NANO, Essential D, GluCora, VCleanzz, Cleanezze and Warts X. The Company develops products in which the components are incorporated into vehicles containing nano-sized delivery vectors, including oil droplets (nanoemulsions), polymeric particles (nanoparticles) and the combination of polymers and lipids with surfactants (hybrid nanoparticles, nanocapsules, mixed micelles). It has its offices in New York, London SF, Cockfosters BP, Los Angeles, Chicago and Las Vegas.

Visit Website

Frequently Asked Questions about ETBI

What is ETBI's current stock price?

Eastgate Biotech Corp. (ETBI) is currently trading at $0.00 per share. The stock has moved +0.00% today.

What is the analyst price target for ETBI?

No analyst price targets are currently available for this stock.

What sector is Eastgate Biotech Corp. in?

Eastgate Biotech Corp. operates in the Healthcare sector, specifically within the Medical - Pharmaceuticals industry. The company is traded on the OTC exchange.

What is ETBI's market cap?

Eastgate Biotech Corp. has a market capitalization of $0.01 billion, making it a small-cap company.

Does ETBI pay dividends?

No, Eastgate Biotech Corp. does not currently pay a dividend to shareholders.